Version 1
: Received: 16 May 2021 / Approved: 18 May 2021 / Online: 18 May 2021 (11:32:07 CEST)
How to cite:
Chakraborty, P.; Chakraborty, K. Anti-Fibrotic Agents Could Be the Game Changer for Post‑COVID Pulmonary Fibrosis Treatment – A Mini Review. Preprints2021, 2021050423. https://doi.org/10.20944/preprints202105.0423.v1
Chakraborty, P.; Chakraborty, K. Anti-Fibrotic Agents Could Be the Game Changer for Post‑COVID Pulmonary Fibrosis Treatment – A Mini Review. Preprints 2021, 2021050423. https://doi.org/10.20944/preprints202105.0423.v1
Chakraborty, P.; Chakraborty, K. Anti-Fibrotic Agents Could Be the Game Changer for Post‑COVID Pulmonary Fibrosis Treatment – A Mini Review. Preprints2021, 2021050423. https://doi.org/10.20944/preprints202105.0423.v1
APA Style
Chakraborty, P., & Chakraborty, K. (2021). Anti-Fibrotic Agents Could Be the Game Changer for Post‑COVID Pulmonary Fibrosis Treatment – A Mini Review. Preprints. https://doi.org/10.20944/preprints202105.0423.v1
Chicago/Turabian Style
Chakraborty, P. and Kaustav Chakraborty. 2021 "Anti-Fibrotic Agents Could Be the Game Changer for Post‑COVID Pulmonary Fibrosis Treatment – A Mini Review" Preprints. https://doi.org/10.20944/preprints202105.0423.v1
Abstract
Total 219 countries and territories globally suffering from the recent pandemic COVID-19 is now in its second wave with more brutality, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) . It has several symptoms like as persistent fever; respiratory illnesses; cough; fatigue; shortness of breath; loss of appetite; persistent pain or pressure in the chest; dysgeusia; acute respiratory distress syndrome (ARDS) etc., and here the things to worry about is the development of pulmonary fibrosis after COVID-19 in both peoples who had died of due to acute respiratory distress syndrome (ARDS) or those who survived. Due to COVID-19, dysregulated immune response and wound repair mainly in elderly patients causes this secondary pulmonary fibrosis. Thus using anti-fibrotic agents could be meaningful in these circumstances although their efficacy in treating COVID-19 is subject to more detailed laboratory research works. In this review article you will get to know about the lung fibrosis generation due to COVID-19 infection, about anti-fibrotic agents and the currents challenges of this field.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
